VRXA — Veraxa Biotech AG - Post de-SPAC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2079109 ·
Switzerland
Last close
$1.04
Market Cap
$147.06M
52W High
$27.36
52W Low
$0.90
ADV30
251,121
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 80,820,364 | 1,613,989 | 96,586,511 |
| Jun 2025 | — | — | — | — | 82,248,288 | 3,315,409 | 69,521,680 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-98,478,340
Inventory
—
Receivables
$1,170,351
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$23,426
EBITDA
$-64,244,176
Free Cash Flow
$15,751,170
Enterprise Value
—
Total Cash
—
Total Debt
—
Shares Out
141,407,813
Trailing EPS
$-0.58
Book Value
$-1.31
ROE
-871.4%
ROA
-50.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 23,426 | -66,216,575 | -66,613,990 | 80,820,364 | 96,586,511 | -15,766,147 | -9,902,331 |
| Dec 2024 | 0 | -28,917,881 | -28,132,971 | 84,766,624 | 53,711,808 | 31,054,816 | -7,720,393 |
| Dec 2023 | 0 | -16,659,993 | -16,544,238 | 91,936,907 | 36,809,163 | 55,127,744 | -7,267,818 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | $146.42M | $1.49 | — |
| RNA | Atrium Therapeutics, Inc. | $139.78M | $6.48 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $138.97M | $1.00 | — |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $155.69M | $1.94 | — |
| SION | Sionna Therapeutics, Inc. | $138.87M | $3.07 | — |
News headlines (Yahoo Finance, 1h cache)
VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
2026-09-22 18:30 · Yahoo
VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline
2026-10-21 19:00 · Yahoo
VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress
2026-10-13 19:30 · Yahoo
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
2026-10-13 11:00 · Yahoo
VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
2026-10-07 19:00 · Yahoo
This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?
2026-10-07 13:58 · Yahoo
Veraxa Biotech stock gains on FDA-aligned testing strategy
2026-10-07 13:29 · Yahoo
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
2026-10-07 11:00 · Yahoo
VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
2026-09-24 19:38 · Yahoo
VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
2026-09-18 19:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.